Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma  by Isogai, Sumito et al.
lable at ScienceDirect
Allergology International xxx (2016) 1e3Contents lists avaiAllergology International
journal homepage: ht tp: / /www.elsevier .com/locate/al i tLetter to the EditorIncreased airway hyperresponsiveness to adenosine in patients with
aspirin intolerant asthmaTable 1
Patient demographics, respiratory function, laboratory ﬁndings, and treatment in
this study.
AIA (n ¼ 12) Non-AIA (n ¼ 18)
Age (mean ± SD) 42.6 ± 17.0 42.1 ± 14.9 n.s.
Male 4 5 n.s.
Atopy (þ/) 6/3 12/6 n.s.
Severity (mild/moderate) 5/7 7/10 n.s.
FVC (ml, mean ± SD) 3006 ± 586 3085 ± 722 n.s.
FEV1.0 (ml, mean ± SD) 2430 ± 537 2365 ± 602 n.s.
FEV1.0% (%, mean ± SD) 81.4 ± 9.2 77.2 ± 6.8 n.s.
%FEV1.0 (%, mean ± SD) 90.3 ± 14.3 85.5 ± 13.3 n.s.
WBC (/ml, mean ± SD) 6300 ± 1500 6900 ± 2200 n.s.
Eosinophil (%, mean ± SD) 9.2 ± 6.3 6.5 ± 2.9 n.s.
IgE (U/ml, mean ± SD) 285.5 ± 272.4 421.3 ± 404.9 n.s.
Therapy n.s.
ICS (mg, mean ± SD) 420 ± 261 360 ± 214 n.s.
LABA (n) 6 5 n.s.
Theophylline (n) 9 13 n.s.Dear Editor,
Airway hyperresponsiveness in bronchial asthma is commonly
evaluated by inhalation of methacholine (Mch) or histamine.
Asthma patients also show bronchoconstriction upon adenosine
inhalation.1 Inhaled adenosine 50-monophosphate (AMP) is con-
verted immediately to adenosine by 50-nucleotidase in the mucosa
of the respiratory tract, which activates mast cells (MCs).2 Direct
bronchial provocation with AMP causes immediate increases in
the concentrations of prostaglandin D2, histamine, and tryptase
in the bronchoalveolar lavage ﬂuid of asthma patients compared
with healthy volunteers.3 Premedication with the MC-stabilizing
drugs cromolyn and nedocromil has been shown to reduce AMP-
induced bronchoconstriction by 9.6- and 22.2-fold, respectively.4
Based on the reports mentioned above, we postulated that AMP-
induced bronchoconstriction is an indirect effect of the histamine
and prostaglandins generated by MC degranulation.5 This type of
bronchoconstriction by AMP may occur via a different mechanism
compared with bronchoconstriction induced by Mch (which stim-
ulates airway smooth muscle directly).
Aspirin-intolerant asthma (AIA) is a type of refractory bronchial
asthma. Even under stable conditions, the number of MCs in the
airway mucosa of AIA patients is z2.5-fold greater than that in
non-AIA patients. Furthermore, levels of a marker of MC activation,
urinary 9a,11b-prostaglandin F2a, are signiﬁcantly higher in AIA
patients.6 Based on these ﬁndings, we hypothesized that MCs
would show greater activation in AIA than in non-AIA, and that
AIA patients would be more hypersensitive to AMP compared
with non-AIA patients. To test these hypotheses, we compared
the results of inhalation challenge tests using AMP and Mch con-
ducted in patients with bronchial asthma diagnosed with AIA or
non-AIA.
The Ethics Committee of Fujita Health University (Toyoake,
Aichi, Japan) approved our study protocol. Study participants
were 30 patients treated for bronchial asthma at an outpatient
clinic in our hospital. Patients who reported an infection of the up-
per respiratory tract or attack of bronchial asthma within 4 weeks
before the examination were excluded from the study. Among
these 30 patients, 12 were diagnosed with AIA (4 males and 8 fe-
males; mean age, 42.6 years) and 18 with non-AIA (5; 13; 42.1
years). Characteristics, laboratory ﬁndings, and therapy of studied
patients are shown in Table 1.Peer review under responsibility of Japanese Society of Allergology.
http://dx.doi.org/10.1016/j.alit.2016.10.001
1323-8930/Copyright © 2016, Japanese Society of Allergology. Production and hosting by Else
licenses/by-nc-nd/4.0/).
Please cite this article in press as: Isogai S, et al., Increased airway hyperre
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tests using tolmetin or sulpyrine; oral aspirin provocation test
with a history of asthma attacks induced by nonsteroidal anti-
inﬂammatory drugs (NSAIDs).7 Patients with a negative result of
the inhalation challenge test using sulpyrine/tolmetin, or oral
aspirin provocation test with no history of NSAID intolerance,
were classiﬁed as “non-AIA”.
For the bronchial provocation test, AMP chloride and Mch (Sig-
maeAldrich; Saint Louis, MO, USA) were dissolved in physiologic
(0.9%) saline in gradually increasing concentrations. Each dilution
was inhaled using a nebulizer, and was interrupted if the
forced expiratory volume in 1 s (FEV1) decreased by 20% from its
baseline value. A concentration of Mch and AMP that achieved a
fall in FEV1 of 20% (PC20) was deﬁned as the index for airway
hyperresponsiveness.
Statistical analyses were undertaken using JMP v8.0 (SAS
Institute, Cary, NC, USA). The ManneWhitney U-test was used to
determine differences in lung function, sex, age, immunoglobulin
(Ig)E value, Mch and AMP thresholds (PC20-AMP and PC20-Mch,
respectively) for airway hyperresponsiveness, and the ratio of PC20-
AMP/PC20-Mch between AIA and non-AIA. We used ANCOVA to
compare the regression coefﬁcient between logPC20-AMP and
logPC20-Mch inAIA andnon-AIA. p<0.05was considered signiﬁcant.LTRA (n) 10 14 n.s.
n.s., not signiﬁcant; ICS, inhaled corticosteroid; LABA, long acting beta agonist; LTRA,
leukotriene receptor antagonist; SD, standard deviation; WBC, white blood cells;
FEV, forced expiratory volume; AIA, aspirin-intolerant asthma.
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Fig. 1. A. The ratio of PC20-AMP/PC20-Mch in AIA patients was signiﬁcantly lower than in non-AIA patients (ManneWhitney U-test, p ¼ 0.007). B. A signiﬁcant positive correlation
was observed between logPC20-AMP and logPC20-Mch in both AIA and non-AIA patients (p < 0.001). Comparative analysis of the two regression slopes showed that individual
PC20-AMP/PC20-Mch was signiﬁcantly lower in AIA than in non-AIA (p ¼ 0.02). C. Receiver Operating Characteristic (ROC) analysis showing the ratio of PC20-AMP/PC20-Mch
is a good marker for discriminating between AIA and non-AIA (ROC AUC: 0.87). The highest speciﬁcity (88.9%) and sensitivity (83.3%) were gained at a cutoff of 15.38 for PC20-
AMP/PC20-Mch.
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with regard to clinical background and lung function (Table 1).
There were no signiﬁcant differences in PC20-AMP and PC20-Mch
between the two groups (data not shown). However, the ratio of
PC20-AMP/PC20-Mch was signiﬁcantly lower than that observed
in non-AIA patients (ManneWhitney U-test, p ¼ 0.007) (Fig. 1A).
A signiﬁcant positive correlation was observed between logPC20-
AMP and logPC20-Mch in AIA and non-AIA patients (r ¼ 0.781
and 1.117, respectively, p < 0.001) (Fig. 1B). Comparative analyses
of the two regression slopes showed that individual PC20-AMP/
PC20-Mch was signiﬁcantly lower in AIA than in non-AIA
(p ¼ 0.02) (Fig. 1B). These results suggested that sensitivity to
AMP was signiﬁcantly higher in AIA patients compared with non-
AIA patients. The ratio of PC20-AMP/PC20-Mch was a good marker
to discriminate between AIA and non-AIA with an area under the
receiver-operating-characteristics curve (ROC AUC) of 0.87. Ana-
lyses of ROC curves showed that the highest speciﬁcity (88.9%)
and sensitivity (83.3%) were gained at a cutoff of 15.38 for PC20-
AMP/PC20-Mch (Fig. 1C).
Recently, it has been recognized that airway MCs have a major
role in AIA pathophysiology.8 Adenosine induces airway hyperres-
ponsiveness through activation of adenosine receptors or P2Y12 re-
ceptors (receptor for adenosine diphosphate and leukotriene E4) on
MCs.9 Genetic polymorphism of the gene for the adenosine recep-
tor has been reported to be associatedwith AIA.10 Taking these ﬁnd-
ings into consideration, it appears that adenosine-induced
bronchoconstriction in AIA is high speciﬁcally because of increased
activation of MCs in the airways of AIA patients.Please cite this article in press as: Isogai S, et al., Increased airway hyperre
Allergology International (2016), http://dx.doi.org/10.1016/j.alit.2016.10.0AIA patients exhibit more severe asthmatic symptoms than
non-AIA patients,8 so the diagnosis and appropriate treatment of
AIA patients is important. A NSAID-challenge test is essential for
the diagnosis of AIA, but is associated with problems such as
sensitivity, speciﬁcity, and risks.7 Thus, several trials to investigate
better diagnostic methods for AIA have been reported. These trials
included in vitro diagnostic methods such as arachidonic-acid de-
rivatives in peripheral blood polymorphonuclear leukocytes or
cluster of differentiation (CD)11b expression on the eosinophil
surface.7
Our study suggests that AIA patients may be more sensitive to
AMP-induced bronchoconstriction than non-AIA patients, and that
bronchial hypersensitivity measured by Mch inhalation was
similar in AIA and non-AIA patients. We speculate that the AMP
provocation test may reﬂect MC activation in the airways of AIA
patients. Differential hyperresponsiveness of airways to inhalation
of AMP and Mch might be a useful marker to distinguish AIA from
non-AIA.Acknowledgments
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